July 5, 2006 -- Sanofi-Aventis will pay up to $360 million for a solid turmor cancer drug from Taiho Pharma; Abbott and AstraZeneca will co-develop a combination cholesterol drug; Tercica won summary judgments in a patent suit lodged against Insmed; Salix submitted information on Colazal; Cell Genesys pointed to a journal article with positive data on Gvax; Favrille said that favorable data on FavId was published in a journal; Pfizer touted data about anti-smoking drug Chantix; Aradigm received $27.5 million from Novo Nordisk for their inhaled insulin drug; TeGenero, a privately held German biotech, filed for bankruptcy after its lead compound caused grave side effects; Oculus Innovative Sciences filed for its IPO; and Medtronic won approval for InterStim II, a smaller stimulator for intractable overactive bladder. The Centient Biotech 200™ was down 23 points at 3652.60, a loss of .62%. More details...
